Herbert Irving Comprehensive Cancer Center
Investigator
Gulam Manji, MD, PhD
Email
gam2140@cumc.columbia.edu

Gulam Manji, M.D., Ph.D. is an Assistant Professor of Medicine at Columbia University Medical Center. Dr. Manji received his M.D. degree from Ross University School of Medicine in 2009 and completed his residency in internal medicine at Albany Medical College. He then completed his fellowship in Hematology/Oncology at NewYork-Presbyterian/Columbia, where his clinical focus was on the treatment of gastrointestinal malignancies, melanoma, and sarcoma under the mentorship of Dr. Gary Schwartz, Chief of Hematology and Oncology.

Dr. Manji conducts translational research with the overall goal to developing new treatments for cancer. His focus is in gastrointestinal malignancies, particularly pancreas adenocarcinoma, on which he is conducting preclinical combination immunotherapy studies on genetically engineered mice with pancreas cancer in the Olive laboratory at the Herbert Irving Comprehensive Cancer Center. The combination immunotherapy preclinical proposal received the Young Investigator Award from the American Society of Clinical Oncology-2015. The goal of these preclinical studies is to bring promising new therapies to the clinic in an early phase clinical trials Dr. Manji's research career in identifying new genes and their implication in disease has led to numerous key publications and an issued patent.

Dr. Manji cares for patients with gastrointestinal malignancies, with a particular focus on pancreatic and liver cancers, and sarcomas. He is the principal investigator of an investigator-initiated multicenter clinical trial that he wrote with Dr. Gary Schwartz in sarcoma and malignant peripheral nerve sheath tumors and is responsible for clinical trials conducted in liver, bile duct, gallbladder, and pancreas cancers at Columbia University Medical Center.


Clinical Studies Managed By This Investigator:
Condition Study Title
Cancer [ CLOSED ] A study patients with metastatic or recurrent Gastric or Gastroesophageal Junction Adencarcinoma using study drug MEDI4736
Liver Cancer [ CLOSED ] A study for patients with biliary or gallbladder cancer using study drug DKN-01
Cancer [ CLOSED ] A Study for patients with recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma using study drug pembrolizumab
Sarcoma A Study for Patients with Malignant Peripheral Nerve Sheath Tumors Using Study Drugs PLX3397 and Sirolimus
Pancreatic Cancer [ CLOSED ] A study for patients with metastatic Pancreatic Cancer using study drug MM-141 plus NabPaclitaxel and Gemcitabine
Liver Cancer [ CLOSED ] A study for patients with liver cancer using study drug RO7070179
Solid Tumors [ CLOSED ] A Study for Patients with Solid Tumors Using Study Drug Atezolizumab
Liver Cancer [ CLOSED ] A study for patients with advanced hepatocellular carcinoma using study drug pembrolizumab
Cancer Study for Patients with Gastric Cancer Using Study Drug Pembrolizumab
Solid Tumors [ CLOSED ] A study for patients with locally advanced or metastatic solid tumors using study drug RO6958688
Solid Tumors [ CLOSED ] A study for patients with gastrointestinal (colon, liver, pancreas, stomach) solid tumors using study drug RO6958688
Pancreatic Cancer Study of Multiple Treatment Combinations in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
Gastrointestinal [ CLOSED ] Study of Treatment Combinations in Patients with Gastric or Gastroesophageal Junction Cancer (Morpheus-Gastric Cancer)
Gastrointestinal [ CLOSED ] Study of Cibisatamab in Combination with Atezolizumab in Patients with Colorectal Cancer
Solid Tumors [ CLOSED ] First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors
Pancreatic Cancer Precision Oncology in Advanced Pancreatic Cancer
Cancer Combination Therapy in KRAS-mutated Advanced Malignancies (MEKiAUTO)
Pancreatic Cancer Chemo4METPANC: Combination Chemotherapy (Gemcitabine and Nab-Paclitaxel), Motixafortide, and Cemiplimab in Pancreas Adenocarcinoma
Cancer LYT-200 Alone and in Combination With Chemotherapy or Anti-PD-1 in Patients With Metastatic Solid Tumors
Cancer Study of AB928 in Combination with Other Therapies for Patients with Metastatic Colon Cancer (mCRC)
Gastrointestinal Study of Pembrolizumab Alone or in Combination with Encorafenib and Cetuximab in Patients with Colon Cancer
Pancreatic Cancer Study of Drug - SBP-101 Alone or in Combination with Chemotherapy in Patients with Untreated Pancreatic Ductal Adenocarcinoma (PDAC)